Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

Abstract

BACKGROUND: Panitumumab in combination with chemotherapy was evaluated in two pivotal clinical trials in first-and second-line treatment of metastatic colorectal cancer (mCRC), respectively. This analysis compared the health-related quality of life (HRQoL) of patients with or without panitumumab in the two trials. METHODS: Patients with mCRC were randomised to FOLFOX (first-line trial) or FOLFIRI (second-line trial)+/- panitumumab. The EuroQoL 5-Dimensions Health State Index (EQ-5D HSI) and Visual Analogue Scale (EQ-5D VAS) were assessed at baseline and monthly follow-up until disease progression. Patients with wild-type KRAS mCRC with baseline and post-baseline HRQoL scores were included. Difference in change from baseline between treatment groups was evaluated using linear mixed and pattern-mixture models. RESULTS: In the first-line trial, 576 patients with wild-type KRAS mCRC (284 panitumumab + FOLFOX4 and 292 FOLFOX4 alone) were included in the HRQoL analyses. In the second-line trial, 530 patients with wild-type KRAS mCRC were included in these analyses (263 panitumumab + FOLFIRI and 267 FOLFIRI alone). There was no significant difference in the change in EQ-5D HSI and VAS scores between treatment groups in either trial. CONCLUSION: The addition of panitumumab to FOLFOX4 or FOLFIRI in first- or second-line treatment of wild-type KRAS mCRC significantly improved progression-free survival without compromising HRQoL. British Journal of Cancer (2011) 105, 1495-1502. doi:10.1038/bjc.2011.409 www.bjcancer.com Published online 11 October 2011 (C) 2011 Cancer Research UK